RVMDWNMS

Revolution Medicines, Inc.

+102.0% · 90d

$4.08

-0.35 (-7.90%)

News

No News Yet

Press releases and SEC filings for RVMDW will appear here as they are published.

Check back later for updates

Key Data

Market Cap—

Open$0.39

Prev Close$4.43

Day Range$4.00 – $4.71

52W Range$4.00 – $4.71

Volume67,067

P/E (TTM)—

EPS—

Dividend Yield—

Beta1.01

About

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

883 employees

www.revmed.com

Top Institutional Holders

As of 2025-12-31 · prior 2025-09-30

FARALLON CAPITAL MANAGEMENT LLC$1.84B

29,208,488 sh+99.7%

VANGUARD GROUP INC$1.33B

16,719,886 sh+6.7%

JANUS HENDERSON GROUP PLC$980.0M

12,303,502 sh+8.3%

BlackRock, Inc.$711.0M

8,926,656 sh+7.2%

BAKER BROS. ADVISORS LP$753.1M

9,455,357 sh0.0%

See all holders →

Quarterly Financials

09/25

Revenue Net Income